XML 73 R37.htm IDEA: XBRL DOCUMENT v3.20.4
The following table provides information about disaggregated revenue, net by product mix for the years ended December 31, 2020, 2019, and 2018: (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2020
 [1]
Sep. 30, 2020
 [2],[3],[4],[5]
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
 [6]
Jun. 30, 2019
 [7]
Mar. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Product Information [Line Items]                      
Net revenue $ 22,577,000 $ 19,343,000 $ 10,701,000 $ 12,251,000 $ 15,902,000 $ 23,719,000 $ 6,079,000 $ 3,947,000 $ 64,872,280 $ 49,646,937 $ 16,099,460
Prescription Vitamins [Member]                      
Product Information [Line Items]                      
Net revenue                 9,767,644 9,885,493 15,041,259
Imvexxy [Member]                      
Product Information [Line Items]                      
Net revenue                 27,139,387 16,252,045 1,058,201
BIJUVA [Member]                      
Product Information [Line Items]                      
Net revenue                 6,353,963 1,836,443
ANNOVERA [Member]                      
Product Information [Line Items]                      
Net revenue                 19,611,286 6,166,556
License [Member]                      
Product Information [Line Items]                      
Net revenue                 $ 2,000,000 $ 15,506,400
[1] During the fourth quarter of 2020, we wrote off approximately $0.5 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.
[2] During the third quarter of 2020, we recorded $2 million in license revenue related to the Knight License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[3] During the third quarter of 2020, we recorded approximately $5.7 million in inventory charge, primarily related to BIJUVA. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[4] During the third quarter of 2020, we recorded the fair value of the Lender Warrants based on Amendment No. 5 of approximately $7.4 million as a debt discount, which is being amortized to interest expense using the effective interest method over the term of the Financing Agreement. Refer to discussion in Note 8-Debt.
[5] During the third quarter of 2020, we wrote off approximately $0.6 million in costs related to trademarks and patents. Refer to discussion in Note 6-Intangible Assets, Net.
[6] During the third quarter of 2019, we recorded approximately $15.5 million in license revenue related to the Theramex License Agreement. Refer to discussion in Note 2-Summary of Significant Accounting Policies.
[7] During the second quarter of 2019, we recorded approximately $10.1 million in loss on extinguishment of debt related to the repayment of the Credit Agreement. Refer to discussion in Note 8-Debt.